Zenocutuzumab, a bispecific antibody that targets HER2 and HER3, showed promising results in the eNRGy study, with an ORR of 29% in NSCLC and 42% in pancreatic cancer, with DOR 11.1 months and mPFS of 6.8 months [148]. This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.